Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Internet healthcare in Chinese public hospitals: Towards high-quality development (1986-present).

AIMS public health·2026
Same author

Relay semi-hydrogenation of acetylene via hydrogen spillover on non-reducible Al<sub>2</sub>O<sub>3</sub>-supported single-atom catalysts.

Nature communications·2026
Same author

A deformable <i>Bacillus subtilis</i> with gut homing for tumor treatment via bacterial metabolism-facilitated synergistic approach for starvation, chemotherapy, and immunotherapy.

Materials today. Bio·2026
Same author

A characteristic length linking oxygen transport and product selectivity in chemical looping methane anaerobic oxidation.

Nature communications·2026
Same author

Two-Dimensional Molybdenum Telluride (MoTe<sub>2</sub>): Synthetic Strategies, Physical Properties, and Future Perspectives.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Protein Corona-Tailored Nanoplatform Boosts Tumor Accumulation and Reprograms Macrophages for Osteosarcoma Therapy.

Nano letters·2026

Related Experiment Video

Updated: Jun 4, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K

Dual-Targeted Drug Delivery to Myeloid Leukemia Cells via Complement- and Transferrin-Based Protein Corona.

Wen Wu1,2, Yuanyuan Li1, Qihui Liu1

  • 1State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Key Laboratory of Pathobiology, Ministry of Education, Nanomedicine and Translational Research Center, China-Japan Union Hospital of Jilin University, Changchun 130033, P. R. China.

Nano Letters
|December 18, 2024
PubMed
Summary

Nanoparticles with agglutinated protein (NAPs) offer a novel approach for targeting acute myeloid leukemia (AML). NAPs enhance drug uptake in leukemic cells while minimizing off-target effects, showing promise for AML therapy.

Keywords:
acute myeloid leukemiacell surface targeting, protein coronacomplement component C3bdrug-loading nanoparticletransferrin

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.2K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.5K

Related Experiment Videos

Last Updated: Jun 4, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.2K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.5K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • The protein corona, often seen as a hurdle, can be leveraged for targeted drug delivery.
  • Acute myeloid leukemia (AML) presents challenges in targeted therapy due to specific cell surface markers.

Purpose of the Study:

  • To develop and evaluate nanoparticles with agglutinated protein (NAPs) for targeted delivery to AML cells.
  • To assess the efficacy and specificity of NAPs in delivering doxorubicin (DOX) to leukemic cells both in vitro and in vivo.

Main Methods:

  • Engineered nanoparticles with agglutinated transferrin and C3b (NAPs) to target CD71 and CD11b receptors.
  • Evaluated DOX uptake and off-target accumulation in leukemic and normal cells in vitro.
  • Assessed NAP biodistribution and antileukemic activity in NSG mouse models (in vivo).

Main Results:

  • NAPs achieved significantly higher doxorubicin uptake (73.9%) in leukemic cells compared to free drug (6.19%).
  • Off-target accumulation in normal cells was reduced from 42.9% to 5.76% with NAPs.
  • NAP distribution correlated with leukemic cell infiltration; demonstrated antileukemic activity via apoptosis and ferroptosis in vitro and in vivo.

Conclusions:

  • NAP-mediated drug delivery is a promising strategy for enhancing AML treatment efficacy.
  • This approach offers improved targeting of leukemic cells and reduced systemic toxicity.